Metformin Beneficial in Lung Cancer Patients With Overweight, Obesity

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 10, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Dec. 10, 2024 -- In non-small cell lung cancer (NSCLC) patients with overweight or obesity, metformin may improve lung cancer-specific clinical outcomes, according to a study published online Nov. 19 in the Journal of the National Cancer Institute.

Randall J. Smith Jr., Ph.D., from the Roswell Park Comprehensive Cancer Center in Buffalo, New York, and colleagues retrospectively analyzed two clinical cohorts and employed contemporary mouse models to examine whether metformin could benefit NSCLC patients with overweight and obesity. One cohort included NSCLC patients with overweight body mass index (BMI) and nonoverweight BMI (511 and 232 individuals, respectively) who underwent lobectomy, and the second examined the effect of metformin on progression-free survival (PFS) after immune checkpoint inhibitor treatment in 284 NSCLC patients with overweight BMI versus 184 NSCLC patients with nonoverweight BMI.

The researchers found that in patients with overweight, there was an association for metformin with increased recurrence-free survival after lobectomy (hazard ratio, 0.47). In diet-induced obese mouse models, metformin corrected accelerated tumor growth in a lymphocyte-specific manner, while reversing certain mechanisms of immune suppression potentiated by obesity. In obese mice, programmed cell death 1 blockade coupled with metformin was more effective at limiting tumor burden; in patients with overweight on immunotherapy, metformin correlated with PFS (hazard ratio, 0.60).

"Our findings demonstrate a need for prospective studies of metformin's effects on high BMI individuals with advanced lung cancer, especially the growing population receiving checkpoint blockade therapy," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-11 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords